Skip to main content

Clinical trial SAFFRON

A phase III, randomised, Open-Label study of Savolitinib in combination with Osimertinib versus platinium-based doublet chemotherapy in participants with EGFR mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who have progressed on treatment with Osimertinib

Cancers
Organ Lung
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor AstraZeneca
EudraCT Identifier 2021-006374-24
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05261399
Last update